Tectonic Therapeutic, Inc. — Director's Dealing 2018

Jun 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVROBIO, Inc. (AVRO)
CIK: 0001681087
Period of Report: 2018-06-25

Reporting Person: SVLSF VI, LLC (10% Owner)
Reporting Person: SV Life Sciences Fund VI, L.P. (10% Owner)
Reporting Person: SV Life Sciences Fund VI Strategic Partners, L.P. (10% Owner)
Reporting Person: SV Life Sciences Fund VI (GP), L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-25	Common Stock	C	2207843	—	Acquired	2207843	Indirect
2018-06-25	Common Stock	C	75591	—	Acquired	75591	Indirect
2018-06-25	Common Stock	C	437611	—	Acquired	2645454	Indirect
2018-06-25	Common Stock	C	14982	—	Acquired	90573	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-25	Series A Preferred Stock	$	C	9122809	Disposed		Common Stock (2207843)	Indirect
2018-06-25	Series A Preferred Stock	$	C	312341	Disposed		Common Stock (75591)	Indirect
2018-06-25	Series B Preferred Stock	$	C	1808211	Disposed		Common Stock (437611)	Indirect
2018-06-25	Series B Preferred Stock	$	C	61908	Disposed		Common Stock (14982)	Indirect

Footnotes

F1: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI, L.P. ("SV Life LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.

F3: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4: The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

F5: Represents the total number of shares of Common Stock received by SV Life LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F6: Represents the total number of shares of Common Stock received by SV Life SP LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F7: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.